EUHASS: The European Haemophilia Safety Surveillance System
Gilman, E A
Hay, C R M
Ludlam, C A
Mannucci, P M
Thrombosis research 2011 Jan; 127 Suppl 2: S22-5
Pharmacovigilance is an essential element of any drug treatment and considering the history of adverse events due to products used to treat inherited bleeding disorders, it should be an integral component of modern haemophilia treatment. Because inherited bleeding disorders and adverse events are rare, a multicentre, preferably multinational, adverse event reporting scheme for all clotting factor products is required. EUHASS is a European, prospective, multicentre adverse event reporting scheme in the field of inherited bleeding disorders.
Showing items related by title, author, creator and subject.
Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy Karimi, M.; Peyvandi, F.; Siboni, S.; Ardeshiri, R.; Gringeri, A.; Mannucci, P.M. (2004-07)
Comments on a Scientific and Animal Welfare Assessment of the OECD Health Effects Test Guidelines for the Safety Testing of Chemicals Under the European Union REACH System Doe, John E.; Lewis, Richard W.; Botham, Philip A. (2006-03)
A Scientific and Animal Welfare Assessment of the OECD Health Effects Test Guidelines for the Safety Testing of Chemicals Under the European Union REACH System Combes, Robert D.; Gaunt, Ian; Balls, Michael (2006-03)